Nothing Special   »   [go: up one dir, main page]

BR112016004355A2 - constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo - Google Patents

constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo

Info

Publication number
BR112016004355A2
BR112016004355A2 BR112016004355A BR112016004355A BR112016004355A2 BR 112016004355 A2 BR112016004355 A2 BR 112016004355A2 BR 112016004355 A BR112016004355 A BR 112016004355A BR 112016004355 A BR112016004355 A BR 112016004355A BR 112016004355 A2 BR112016004355 A2 BR 112016004355A2
Authority
BR
Brazil
Prior art keywords
fab
present
poly
effector fusion
preparation
Prior art date
Application number
BR112016004355A
Other languages
English (en)
Inventor
Cha Sanghoon
Original Assignee
Aprilbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co Ltd filed Critical Aprilbio Co Ltd
Publication of BR112016004355A2 publication Critical patent/BR112016004355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo da patente de invenã§ã£o para: “constructo de fusãƒo de parte efetora de fab anti-soroalbumina e mã‰todo de preparaã‡ãƒo do mesmo.” a presente invenã§ã£o refere-se a um seu fragmento de ligaã§ã£o a antã­geno (fab) e uma proteã­na ou (poli)peptã­deo de fusã£o efetores de fab compreendendo os mesmos. o fab da presente invenã§ã£o se liga especificamente ã  seroalbumina e dessa forma aumenta a meia-vida in vivo. o fab da presente invenã§ã£o ã© caracterizado por nã£o ter resã­duos de cisteã­na que sã£o responsã¡veis pela ligaã§ã£o dissulfureto intercadeias no domã­nio ch1 e domã­nio cîºl tambã©m. a proteã­na ou o (poli)peptã­deo de fusã£o efetores de fab da presente invenã§ã£o podem ser produzidos no periplasma de e. coli com um rendimento elevado, e apresenta aumentada meia-vida in vivo. alã©m disso, a presente invenã§ã£o proporciona a cepa de e. coli que produz vã¡rios tipos de proteã­nas ou (poli)peptã­deos de fusã£o efetores de fab, e uma composiã§ã£o farmacãªutica compreendendo as proteã­nas ou (poli)peptã­deos de fusã£o efetores de fab.
BR112016004355A 2013-08-30 2014-08-29 constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo BR112016004355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Publications (1)

Publication Number Publication Date
BR112016004355A2 true BR112016004355A2 (pt) 2017-10-17

Family

ID=52586989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004355A BR112016004355A2 (pt) 2013-08-30 2014-08-29 constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo

Country Status (17)

Country Link
US (2) US9879077B2 (pt)
EP (2) EP3632930A1 (pt)
JP (2) JP6422977B2 (pt)
KR (2) KR101576561B1 (pt)
CN (1) CN105899532B (pt)
AU (1) AU2014312456B2 (pt)
BR (1) BR112016004355A2 (pt)
CA (1) CA2922618C (pt)
DK (1) DK3039038T3 (pt)
ES (1) ES2866848T3 (pt)
HK (1) HK1223107A1 (pt)
MX (1) MX371328B (pt)
PH (1) PH12016500403A1 (pt)
PL (1) PL3039038T3 (pt)
RU (1) RU2661087C2 (pt)
UA (1) UA117493C2 (pt)
WO (1) WO2015030539A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CN112368015A (zh) * 2018-06-18 2021-02-12 安维达生物科技公司 细胞因子融合蛋白及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
AR129610A1 (es) * 2022-06-15 2024-09-11 UCB Biopharma SRL Proteínas de fusión
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP1791866A2 (en) * 2004-08-11 2007-06-06 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
WO2006041641A2 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
MX2007006602A (es) * 2004-12-02 2007-12-10 Domantis Ltd Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio.
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
EP2160405A2 (en) * 2007-06-08 2010-03-10 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
ES2622460T3 (es) * 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
KR20110008086A (ko) * 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
MX2011005874A (es) * 2008-12-05 2011-06-27 Glaxo Group Ltd Metodos para seleccionar polipeptidos resistentes a proteasa.
EP2461831B1 (en) * 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR112014011304B1 (pt) * 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso

Also Published As

Publication number Publication date
CN105899532B (zh) 2021-10-08
WO2015030539A1 (en) 2015-03-05
KR101576561B1 (ko) 2015-12-10
EP3039038A1 (en) 2016-07-06
RU2016105586A (ru) 2017-10-04
EP3039038B1 (en) 2020-11-25
PH12016500403A1 (en) 2016-05-16
EP3632930A1 (en) 2020-04-08
CA2922618A1 (en) 2015-03-05
US20160376350A1 (en) 2016-12-29
JP6800180B2 (ja) 2020-12-16
ES2866848T3 (es) 2021-10-19
JP2016528922A (ja) 2016-09-23
MX2016002539A (es) 2016-10-13
AU2014312456A1 (en) 2016-03-03
EP3039038A4 (en) 2017-07-05
US9879077B2 (en) 2018-01-30
MX371328B (es) 2020-01-27
DK3039038T3 (da) 2021-02-08
JP6422977B2 (ja) 2018-11-14
US10618953B2 (en) 2020-04-14
RU2661087C2 (ru) 2018-07-11
KR20150118565A (ko) 2015-10-22
CN105899532A (zh) 2016-08-24
UA117493C2 (uk) 2018-08-10
US20180030127A1 (en) 2018-02-01
PL3039038T3 (pl) 2021-04-19
AU2014312456A8 (en) 2016-03-17
JP2018172391A (ja) 2018-11-08
AU2014312456B2 (en) 2017-07-06
CA2922618C (en) 2020-04-28
HK1223107A1 (zh) 2017-07-21
KR20150026997A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
BR112016004355A2 (pt) constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201391753A1 (ru) Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX2017006866A (es) Pares de unión para producción de péptidos.
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA201591700A1 (ru) Гибридные белки апелина и их применение
PE20090831A1 (es) Anticuerpo monoclonal
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20190733A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
WO2017060322A3 (en) Ptefb-inhibitor-adc
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
HRP20170905T1 (hr) Antikancerogeni fuzijski protein
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
CA2866232A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
PE20081687A1 (es) Proteina de fusion
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
AR111764A1 (es) Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023013900-3 PROTOCOLO 870230060709 EM 11/07/2023 16:35.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]